Agency issues alert about Thermo Fisher’s TaqPath genetic test
TUESDAY, Aug. 18, 2020 (HealthDay News) — A widely used COVID-19 test could produce inaccurate results due to issues with the equipment and software used to run the test, the U.S. Food and Drug Administration warned Monday.
The agency issued the alert about Thermo Fisher’s TaqPath genetic test.
The company is working with the FDA “to make sure that laboratory personnel understand the need for strict adherence to the instructions for use,” according to a spokeswoman for Thermo Fisher.
The FDA did not reveal how many inaccurate test results there have been.
Retinal Imaging Can ID Atrial Fibrillation Years Before Diagnosis 
U.S. Adults May Not Understand Their Risk for Vascular Disease 
Screening + Online Cognitive Behavioral Therapy Program Aids Nurses" Mental Health 
Autism Spectrum Disorder Diagnoses Increased for Females Since 2020 
People With Autism Have Shorter Life Expectancy 
Virtual Reality-Based Digital Defocus Vision Training May Aid Myopia in Children 
Paternal Exposure to Valproate Not Linked to Offspring Neurodevelopmental Disorders 
Internet-Based Cognitive-Behavioral Therapy Aids Children"s Anxiety Symptoms 
